The CALML5 antibody is designed to target CALML5 (Calmodulin-like protein 5), a member of the calmodulin family of calcium-binding proteins. CALML5. also known as calmodulin-like skin protein (CLSP), is a small, highly conserved 16 kDa protein predominantly expressed in epidermal tissues, particularly in the granular and cornified layers of the skin. It plays a critical role in regulating epidermal differentiation and barrier function by interacting with proteins involved in keratinocyte maturation and cornification. Studies suggest CALML5 is downregulated in psoriasis and other hyperproliferative skin disorders, highlighting its importance in maintaining skin homeostasis. Additionally, CALML5 has been implicated as a potential tumor suppressor in certain cancers, including esophageal squamous cell carcinoma, where its epigenetic silencing correlates with poor prognosis. The CALML5 antibody is widely used in immunohistochemistry (IHC), Western blotting (WB), and immunofluorescence (IF) to investigate its tissue-specific expression, subcellular localization, and interactions with signaling pathways. Researchers employ this tool to explore CALML5's role in epithelial differentiation, calcium-mediated signaling, and disease mechanisms, offering insights into therapeutic strategies for skin disorders and malignancies linked to its dysregulation.